318 Olaparib plus pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation and/or homologous recombination repair deficiency: KEYLYNK-007

• Andrew E Hendifar,
• Douglas A Levine,
• Ronnie Shapira-Frommer,
• Sanatan Saraf,
• Michele Maio,
• Timothy A Yap,
• Mallika Dhawan,
• Taofeek K Owonikoko,
• Miguel Quintela-Fandino,
• Ping Qiu,
• Fan Jin,
• Alexander Gozman

Affiliations

Andrew E Hendifar

3Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA

Douglas A Levine

9Laura and Isaac Perlmutter Cancer Center, New York, NY, USA

Ronnie Shapira-Frommer

7Chaim Sheba Medical Center, Tel HaShomer, Israel

Sanatan Saraf

8Merck and Co., Inc., Kenilworth, NJ, USA

Michele Maio

4Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy

Timothy A Yap

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Mallika Dhawan

2Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA

Taofeek K Owonikoko

5Winship Cancer Institute, Emory University, Atlanta, GA, USA

Miguel Quintela-Fandino

6Centro Nacional de Investigaciones Oncológicas, Madrid, Spain

Ping Qiu

8Merck and Co., Inc., Kenilworth, NJ, USA

Fan Jin

8Merck and Co., Inc., Kenilworth, NJ, USA

Alexander Gozman

8Merck and Co., Inc., Kenilworth, NJ, USA